

Trends Underlying Positive and Negative Decision-Making for New Oncology Treatments Appraised by NICE in 2023

Stothard, CA; Bodke, A; Crossley, O; Knott, C; Samuels, E;
Tang, M.

[HTA53: Supplementary Materials](#)



Table 1: Included NICE TA and HST for oncology treatments published in 2023

Reference ID	Date guidance was last updated	Title
TA939	2023-12-13	Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
TA931	2023-11-22	Zanubrutinib for treating chronic lymphocytic leukaemia
TA930	2023-11-15	Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments
TA928	2023-11-02	Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine
TA917	2023-10-25	Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable
TA921	2023-10-18	Ruxolitinib for treating polycythaemia vera
TA927	2023-10-17	Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments
TA914	2023-09-20	Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency
TA911	2023-07-26	Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer
TA909	2023-07-12	Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer
TA908	2023-07-05	Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy
TA903	2023-06-21	Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer
TA904	2023-06-21	Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer
TA898	2023-06-15	Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer

Reference ID	Date guidance was last updated	Title
TA894	2023-06-07	Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma
TA895	2023-06-07	Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy
TA893	2023-06-07	Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over
TA897	2023-06-06	Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
TA891	2023-05-31	Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia
TA892	2023-05-31	Mosunetuzumab for treating relapsed or refractory follicular lymphoma
TA886	2023-05-10	Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy
TA887	2023-05-10	Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer
TA881	2023-05-03	Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatment
TA883	2023-05-03	Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma
TA876	2023-03-22	Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer
TA874	2023-03-01	Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma
TA872	2023-02-28	Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
TA870	2023-02-22	Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
TA865	2023-02-08	Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma

Reference ID	Date guidance was last updated	Title
TA866	2023-02-08	Regorafenib for previously treated metastatic colorectal cancer
TA862	2023-02-01	Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments
TA858	2023-01-11	Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments
TA857	2023-01-11	Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma

Abbreviations: HST: highly specialised technology; ID: identification; TA: technology appraisal.